rVSVΔG-ZEBOV-GP

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Epicentre

Conditions

Ebola Virus Disease

Phase 2

Partnership for Research on Ebola VACcinations

CompletedNCT02876328

National Institute of Allergy and Infectious Diseases (NIAID)Ebola Virus Disease

Start: 2017-03-27End: 2023-12-20Updated: 2024-06-26

Phase 3

Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine

CompletedNCT03161366

EpicentreEbola Virus Disease

Start: 2018-05-28End: 2018-11-30Updated: 2018-12-19

Related Papers

Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial

PLoS neglected tropical diseases2026-01-30

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Emerging Microbes & Infections2024-11-192 citations

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.

2024-09-038 citations

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study

Vaccines2024-02-176 citations

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Clinical Infectious Diseases2023-11-1314 citations

Randomized Trial of Vaccines for Zaire Ebola Virus Disease

New England Journal of Medicine2022-12-1468 citations

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.

2021-09-1361 citations

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.

2021-01-2310 citations

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

The Journal of Infectious Diseases2018-11-0482 citations